The GLP-1 shopping process got messier in 2026, not simpler. Warning letters, brand-name settlement pressure, and new oral-drug pricing all landed close together, which made pharmacy identity and real cash price matter more than polished signup pages.
Here is where ten real options stand right now, grouped by what they actually do best.
Best for Cash-Pay Value
HealthRX
Compounded semaglutide starting at $99 per month. Compounded tirzepatide from $149. Those are among the lowest published entry prices in this category, and the pharmacy behind the prescriptions is named: Manifest Pharmacy in Greer, South Carolina, a 503A/USP-797 facility with lot-level tracking from production to delivery.
That matters because plenty of telehealth brands do not disclose their dispensing pharmacy at all. Manifest is also LegitScript-certified (cert 50087439), which is a voluntary third-party verification most small compounders skip. The clinical model is straightforward: complete an online health intake, a U.S. board-certified physician reviews the case within roughly 24 hours, and medication ships overnight at no extra charge to all 50 states.
The efficacy numbers HealthRX references are trial-based, not proprietary claims. SURMOUNT-1 showed tirzepatide participants losing an average of roughly 21% of body weight over 72 weeks. The STEP 1 semaglutide trial showed roughly 15% at 68 weeks. These compounds are not FDA-approved products, and HealthRX does not claim otherwise.
For someone paying out of pocket, this combination of verified pharmacy sourcing, fast turnaround, and honest pricing is hard to match at this price point.
MEDVi
Around $179 for month one, no contracts, compounded GLP-1s. Lighter on monitoring than some competitors but straightforward for people who want to start without a long onboarding process.
Best for Published Purity Data and Peptide Access
FormBlends
Not the cheapest option here. A single vial of compounded semaglutide runs approximately $299, tirzepatide approximately $349. FormBlends earns its spot for a different reason: it publishes per-product quality data including HPLC purity percentages, mass spec identity confirmation, and endotoxin and sterility results, with actual numbers attached.
Most GLP-1 telehealth platforms say their compounding pharmacy follows USP standards. FormBlends shows the test results. For anyone who has read about quality-control failures at unlicensed peptide labs, that distinction is real. Dispensing goes through an FDA-registered 503A compounding pharmacy, and clinician oversight is built into the model.
Ships to 47 states, not 50, which is a genuine limitation compared to HealthRX. The other differentiator is breadth: FormBlends also offers a peptide catalog covering recovery, longevity, and cognitive-support compounds under the same clinical framework. That makes it the better fit for someone who wants GLP-1 therapy and access to other peptides from a single provider.
Honest summary: HealthRX wins on price and national reach. FormBlends wins when purity documentation and a wider catalog matter more than entry cost.
Best for Insurance Coverage and Branded Meds
Hims & Hers
After exiting compounded GLP-1 following the March 2026 Novo settlement, Hims & Hers now focuses on branded medications. Injectable Wegovy is listed at roughly $299 per month, oral semaglutide around $249, Zepbound around $399. With insurance and manufacturer savings cards, some users report costs as low as $0 to $25 per month. Good infrastructure, recognizable brand, limited value for cash payers.
PlushCare
Membership at $19.99 per month, branded meds billed through insurance where possible, same-day appointment availability. PlushCare functions more like a standard telehealth primary care service that happens to prescribe GLP-1s, which can be an advantage if you want those prescriptions integrated with broader health management.
Ro / Ro Body
First month around $39, then $74 to $149, with medications billed separately. Ro has a dedicated prior-authorization team to help members pursue insurance coverage for branded drugs. That is a specific, useful service that most cash-pay compounders cannot offer.
Best for Monitoring and Coaching
Mochi Health
Compounded semaglutide at $99 per month, tirzepatide at $199. Mochi stands out for using board-certified obesity-medicine clinicians rather than general practitioners. More clinical check-ins than many platforms at this price range.
Form Health
The premium end. Around $299 per month plus labs and medication costs. Members work with both a physician and a registered dietitian on the same care team. Expensive, but this is the closest thing in telehealth to what a dedicated obesity-medicine practice offers.
Calibrate
Structured 12-month program with coaching baked in and medications billed separately. Appeals to people who want accountability built into the product rather than bolted on.
Best for Budget Flexibility
Found
Around $99 per month for the platform, medications priced separately. Coaching included. Positioned between the bare-bones compounders and the full-service programs.
Sesame
From roughly $59 per month on an annual plan, medications separate. Sesame functions as a broader telehealth marketplace, so GLP-1 prescribing is one service among many. Useful if you want flexibility or already use the platform for other care.
A Quick Note Before You Book
Compounded medications, including semaglutide and tirzepatide from any telehealth platform, are not FDA-approved drug products. Compounding pharmacies operate under a different regulatory framework. Efficacy data cited by these platforms comes from clinical trials of the branded drugs, not the compounded versions. Anyone considering GLP-1 therapy should review contraindications with a physician, particularly anyone with a personal or family history of medullary thyroid carcinoma or pancreatitis. Prices listed here reflect publicly available information as of mid-2026 and may have changed.
Common Questions
Is compounded semaglutide from platforms like HealthRX or MEDVi the same drug as Ozempic or Wegovy?
No. Compounded semaglutide contains the same active molecule but is not the FDA-approved branded product. It is manufactured by a 503A compounding pharmacy under a different regulatory pathway. Clinical trial data on weight loss comes from trials of the branded drugs, not from compounded versions, which have not been separately tested in large outcome studies.
How do I tell whether a compounding pharmacy used by one of these telehealth services is legitimate?
Look for two things: whether the platform names the pharmacy at all, and whether that pharmacy holds 503A or 503B FDA registration. LegitScript certification, which HealthRX’s dispensing partner Manifest Pharmacy holds, is an additional voluntary verification layer. Platforms that refuse to name their pharmacy are a genuine red flag worth taking seriously.
After the March 2026 Novo Nordisk settlement, which of these platforms still offer compounded GLP-1s?
Hims & Hers exited compounded GLP-1 following the settlement and now focuses on branded medications. As of mid-2026, platforms including HealthRX, MEDVi, FormBlends, Mochi Health, and Found were still offering compounded semaglutide or tirzepatide, though regulatory conditions in this space can change quickly and you should verify current offerings directly.
If my insurance might cover Wegovy or Zepbound, which platform here is best positioned to help me use it?
Ro has a dedicated prior-authorization team specifically for this purpose, which sets it apart from most cash-pay compounders. PlushCare and Hims & Hers also work with insurance for branded medications. Form Health operates at the premium end and integrates physician and dietitian care, which can support insurance documentation if your plan requires evidence of supervised treatment.
What is the real difference between a platform like Form Health at $299 per month and one like HealthRX at $99 per month?
Price buys different things here. HealthRX covers medication plus clinical review at a low cash price with named pharmacy sourcing. Form Health charges $299 for the platform alone, before labs and medication, but pairs you with both a physician and a registered dietitian working together. That level of coordinated oversight is closer to what a brick-and-mortar obesity-medicine clinic provides, and it matters most for people with complex health histories or who have not succeeded with self-directed approaches.
Sources
- FDA Warning Letters to Telehealth and Compounding Firms, early 2026, FDA.gov
- SURMOUNT-1 trial (tirzepatide), published in NEJM, 2022
- STEP 1 trial (semaglutide), published in NEJM, 2021
- Novo Nordisk settlement announcement, March 9, 2026, Novo Nordisk press releases
- LegitScript pharmacy certification database, LegitScript.com
- Lilly orforglipron / LillyDirect pricing announcement, April 2026, Eli Lilly press materials
